NCT03071081已完成1 期
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TOP1288 Oral Single Ascending and Multiple Doses in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Safety (vital signs)
研究概览
简要总结
This study evaluates the safety and tolerability of TOP1288 oral single ascending and multiple doses in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Subject is a healthy male, aged between 18 and 55 years of age (inclusive) at Screening.
- •Subject has a body mass index (BMI) of between 18.0 and 29.9 kg/m2 (inclusive), with a body weight of at least 50 kg at Screening.
- •Subject is in good physical and mental health in the opinion of the Investigator.
- •Subject has clinical laboratory test results within the reference ranges of the testing laboratory unless results outside the reference ranges are deemed not clinically significant by the Investigator at Screening and Day -
- •Subject has a supine blood pressure and pulse rate within the normal range after 5 minutes' rest (systolic blood pressure: 90 to 140 mmHg, diastolic blood pressure: 40 to 90 mmHg, pulse rate: 40 to 90 beats per minute) at Screening and Day -
- •Subjects must be willing to comply with the contraception restrictions of the protocol for this study.
- •Subject has regular bowel opening of usually 1 motion per day of normal consistency.
排除标准
- •Subject has participated in another study of an investigational medication (or a medical device) within the last 3 months or 5 half-lives of the investigational medication, whichever is longer, prior to the first day or dosing.
- •Subject has made a blood donation (> 400 mL) or had a comparable blood loss (> 350 mL) within the last 3 months prior to first administration of study drug.
- •Subject tests positive for human immunodeficiency virus (HIV)-1/2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies at Screening.
- •Subject has a history of alcohol and/or drug abuse.
- •Subject has an alcohol consumption of more than 21 units of alcohol per week.
- •Subject tests positive for alcohol and/or drugs (urine tests) at Screening or admission.
- •Subject has received any prescription or non-prescription medications, including over-the-counter medications, nutraceuticals (e.g., St. John's Wort, ginseng, kava kava, Ginkgo biloba and melatonin), foods or beverages containing grapefruit and vitamin supplements within 14 days prior to admission (Day -1) or nutraceuticals containing caffeine- or xanthine-related substances within 72 hours prior to admission (Day -1). Foods or beverages containing Seville-type (sour) oranges, or poppy seeds are also excluded within this time period.
- •The subject has a history of daily consumption of 5 or more cups of coffee or tea.
- •Subject has a known hypersensitivity to any components of the study drug.
- •Subject has any history of any clinically significant acute or chronic condition affecting the colon and/or rectum and/or anus, including haemorrhoids and irritable bowel syndrome, sufficient to cause symptoms and/or that in the judgement of the PI and the Sponsor's study Physician/Medical Monitor would interfere with the subject's participation in the study.
- •Any findings on pre-dose endoscopy that in the PI's judgement would interfere with subject participation in the study.
- •Subject has acute or chronic condition affecting GI motility such as constipation or diarrhoea that would, in the judgement of the PI and the Sponsor's study Physician/Medical Monitor, interfere with the subject's participation in the study
- •Subject has cardiovascular or cerebrovascular disease, including hypertension, angina, ischaemic heart disease, transient ischaemic attacks, stroke and peripheral arterial disease sufficient to cause symptoms and/or require therapy to maintain stable status.
- •Subject has an active infection (e.g., sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalisation or requiring parenteral antibiotic treatment) within 6 weeks prior to study drug administration.
- •Subject has a history of positive tuberculosis test or evidence of possible tuberculosis or latent tuberculosis infection at Screening (interferon gamma release assay testing) that cannot be attributed to a prior Bacillus Calmette-Guérin inoculation.
- •Subject has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study.
- •Subject has any of the following haematology values at Screening or Day -1:
- •Haemoglobin, < 13 g/dL.
- •Absolute neutrophil count < 1.5 x 109/L (< 1500/μL).
- •Subject has a 12-lead electrocardiogram (ECG) with results considered to be potentially clinically significant, e.g., QTcF > 450 ms, bundle branch block, evidence of myocardial ischaemia, at Screening or Day -
- •Subject has an abnormality in the ECG that, in the opinion of the Investigator, increases the risks associated with participating in the study.
- •Subject has renal or liver impairment at Screening or Day -1, defined as:
- •Serum creatinine level ≥ 135 μmol/L, or
- •Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥2 x upper limit of normal, or
- •Alkaline phosphate and/or bilirubin > 1.5 x upper limit of normal (an isolated bilirubin 1.5 x upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin is < 35%).
- •Subject has active neoplastic disease or history of any neoplastic disease within 5 years of Screening (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care).
- •Subject has any other acute or chronic illness which, in the opinion of the Investigator or Sponsor's study Physician/Medical Monitor, could pose a threat or harm to the subject's participation in the study.
- •The subject has used nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, nicotine patch, or nicotine gum) within 2 weeks prior to admission to the study centre (Day -1).
研究组 & 干预措施
Placebo to TOP1288 200mg BID
Placebo Comparator
1 day dosing
干预措施: Placebo to TOP1288 (Drug)
TOP1288 200mg BID
Experimental
1 day dosing
干预措施: TOP1288 (Drug)
TOP1288 1g BID
Experimental
1 day dosing
干预措施: TOP1288 (Drug)
Placebo to TOP1288 1g BID
Placebo Comparator
1 day dosing
干预措施: Placebo to TOP1288 (Drug)
TOP1288 Xg (where X is <=1g) BID
Experimental
7 days dosing
干预措施: TOP1288 (Drug)
Placebo to TOP1288 Xg
Placebo Comparator
7 days dosing
干预措施: Placebo to TOP1288 (Drug)
结局指标
主要结局
Safety (vital signs)
时间窗: To 7 days after last dose
As measured by vital signs
Safety (clinical lab tests)
时间窗: To 7 days after last dose
As measured by clinical laboratory tests
Safety (AEs)
时间窗: To 7 days after last dose
As measured by adverse events
Safety (ECGs)
时间窗: To 7 days after last dose
As measured by ECGs
次要结局
- Pharmacokinetic profile AUC0-24h(0-24 hours)
- Pharmacokinetic profile tmax(0-48 hours)
- Pharmacokinetic profile AUC0-t(0-48 hours)
- Pharmacokinetic profile AUC0-12h(0-12 hours)
- Pharmacokinetic profile t½(0-48 hours)
- Pharmacokinetic profile λz(0-48 hours)
- Pharmacokinetic profile Cmax(0-48 hours)
- Pharmacokinetic profile AUC(0-48 hours)
- Pharmacokinetic profile Vz/F(0-48 hours)
- Pharmacokinetic profile Racc(0-48 hours)
- Pharmacokinetic profile CL/F(0-48 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis SubjectsUlcerative ColitisNCT02463045Topivert Pharma Ltd67
已完成
1 期
Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDNPainful Diabetic NeuropathyNCT04857957Centrexion Therapeutics46
已完成
1 期
Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202Parkinson's DiseaseNCT02763787Bial - Portela C S.A.71
终止
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205Healthy SubjectsPharmacokinetics of ASP2205NCT02314793Astellas Pharma Europe B.V.93
终止
1 期
A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female SubjectsPharmacokinetics of ASP7657Pharmacodynamics of ASP7657Healthy SubjectsNCT02108548Astellas Pharma Europe B.V.89